CA2783550A1 - Improved methods of cell culture for adoptive cell therapy - Google Patents
Improved methods of cell culture for adoptive cell therapy Download PDFInfo
- Publication number
- CA2783550A1 CA2783550A1 CA2783550A CA2783550A CA2783550A1 CA 2783550 A1 CA2783550 A1 CA 2783550A1 CA 2783550 A CA2783550 A CA 2783550A CA 2783550 A CA2783550 A CA 2783550A CA 2783550 A1 CA2783550 A1 CA 2783550A1
- Authority
- CA
- Canada
- Prior art keywords
- cells
- cell
- surface density
- growth
- culture
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
- 238000000034 method Methods 0.000 title claims abstract description 67
- 230000001976 improved effect Effects 0.000 title claims abstract description 9
- 238000004113 cell culture Methods 0.000 title description 7
- 238000011467 adoptive cell therapy Methods 0.000 title description 2
- 210000004027 cell Anatomy 0.000 claims abstract description 424
- 230000012010 growth Effects 0.000 claims abstract description 101
- 238000004519 manufacturing process Methods 0.000 claims abstract description 86
- 210000000612 antigen-presenting cell Anatomy 0.000 claims abstract description 36
- 239000000463 material Substances 0.000 claims abstract description 29
- 238000002659 cell therapy Methods 0.000 abstract description 13
- 238000012258 culturing Methods 0.000 abstract description 10
- 239000002609 medium Substances 0.000 description 63
- 238000007796 conventional method Methods 0.000 description 53
- 210000001744 T-lymphocyte Anatomy 0.000 description 45
- 239000000427 antigen Substances 0.000 description 43
- 108091007433 antigens Proteins 0.000 description 43
- 102000036639 antigens Human genes 0.000 description 43
- 239000000203 mixture Substances 0.000 description 34
- 239000007789 gas Substances 0.000 description 33
- 210000003819 peripheral blood mononuclear cell Anatomy 0.000 description 17
- 230000000638 stimulation Effects 0.000 description 14
- 230000008901 benefit Effects 0.000 description 13
- 230000008569 process Effects 0.000 description 13
- 230000002829 reductive effect Effects 0.000 description 10
- 238000003556 assay Methods 0.000 description 9
- 230000010261 cell growth Effects 0.000 description 9
- 238000012360 testing method Methods 0.000 description 9
- 108090000765 processed proteins & peptides Proteins 0.000 description 8
- 239000012737 fresh medium Substances 0.000 description 7
- 238000010186 staining Methods 0.000 description 7
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 6
- 238000013459 approach Methods 0.000 description 6
- 230000003442 weekly effect Effects 0.000 description 6
- 108010002350 Interleukin-2 Proteins 0.000 description 5
- 238000004458 analytical method Methods 0.000 description 5
- 238000010790 dilution Methods 0.000 description 5
- 239000012895 dilution Substances 0.000 description 5
- LOKCTEFSRHRXRJ-UHFFFAOYSA-I dipotassium trisodium dihydrogen phosphate hydrogen phosphate dichloride Chemical compound P(=O)(O)(O)[O-].[K+].P(=O)(O)([O-])[O-].[Na+].[Na+].[Cl-].[K+].[Cl-].[Na+] LOKCTEFSRHRXRJ-UHFFFAOYSA-I 0.000 description 5
- 230000000977 initiatory effect Effects 0.000 description 5
- 230000000670 limiting effect Effects 0.000 description 5
- 239000002953 phosphate buffered saline Substances 0.000 description 5
- 230000008859 change Effects 0.000 description 4
- 230000003247 decreasing effect Effects 0.000 description 4
- 239000012091 fetal bovine serum Substances 0.000 description 4
- 230000006870 function Effects 0.000 description 4
- 210000000822 natural killer cell Anatomy 0.000 description 4
- 238000010899 nucleation Methods 0.000 description 4
- 230000004936 stimulating effect Effects 0.000 description 4
- 210000003171 tumor-infiltrating lymphocyte Anatomy 0.000 description 4
- 230000035899 viability Effects 0.000 description 4
- -1 CD86 Proteins 0.000 description 3
- VYZAMTAEIAYCRO-UHFFFAOYSA-N Chromium Chemical compound [Cr] VYZAMTAEIAYCRO-UHFFFAOYSA-N 0.000 description 3
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 3
- 101001136981 Homo sapiens Proteasome subunit beta type-9 Proteins 0.000 description 3
- 241000701044 Human gammaherpesvirus 4 Species 0.000 description 3
- 108010004729 Phycoerythrin Proteins 0.000 description 3
- 102100035764 Proteasome subunit beta type-9 Human genes 0.000 description 3
- 238000001190 Q-PCR Methods 0.000 description 3
- 239000012980 RPMI-1640 medium Substances 0.000 description 3
- 230000032823 cell division Effects 0.000 description 3
- 230000003833 cell viability Effects 0.000 description 3
- 229910052804 chromium Inorganic materials 0.000 description 3
- 239000011651 chromium Substances 0.000 description 3
- 230000001186 cumulative effect Effects 0.000 description 3
- 230000003467 diminishing effect Effects 0.000 description 3
- 238000002474 experimental method Methods 0.000 description 3
- 238000000684 flow cytometry Methods 0.000 description 3
- 238000011534 incubation Methods 0.000 description 3
- 230000002147 killing effect Effects 0.000 description 3
- 238000002372 labelling Methods 0.000 description 3
- 235000015097 nutrients Nutrition 0.000 description 3
- 230000002062 proliferating effect Effects 0.000 description 3
- 230000009467 reduction Effects 0.000 description 3
- 230000000284 resting effect Effects 0.000 description 3
- 230000003068 static effect Effects 0.000 description 3
- YBJHBAHKTGYVGT-ZKWXMUAHSA-N (+)-Biotin Chemical group N1C(=O)N[C@@H]2[C@H](CCCCC(=O)O)SC[C@@H]21 YBJHBAHKTGYVGT-ZKWXMUAHSA-N 0.000 description 2
- 102100022005 B-lymphocyte antigen CD20 Human genes 0.000 description 2
- 102100027207 CD27 antigen Human genes 0.000 description 2
- 101100455063 Caenorhabditis elegans lmp-1 gene Proteins 0.000 description 2
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 2
- 108010031111 EBV-encoded nuclear antigen 1 Proteins 0.000 description 2
- 108091034120 Epstein–Barr virus-encoded small RNA Proteins 0.000 description 2
- 101000897405 Homo sapiens B-lymphocyte antigen CD20 Proteins 0.000 description 2
- 101000914511 Homo sapiens CD27 antigen Proteins 0.000 description 2
- 101001057504 Homo sapiens Interferon-stimulated gene 20 kDa protein Proteins 0.000 description 2
- 101001055144 Homo sapiens Interleukin-2 receptor subunit alpha Proteins 0.000 description 2
- 101001018097 Homo sapiens L-selectin Proteins 0.000 description 2
- 101000914484 Homo sapiens T-lymphocyte activation antigen CD80 Proteins 0.000 description 2
- 102100026878 Interleukin-2 receptor subunit alpha Human genes 0.000 description 2
- ZDXPYRJPNDTMRX-VKHMYHEASA-N L-glutamine Chemical compound OC(=O)[C@@H](N)CCC(N)=O ZDXPYRJPNDTMRX-VKHMYHEASA-N 0.000 description 2
- 229930182816 L-glutamine Natural products 0.000 description 2
- 102100033467 L-selectin Human genes 0.000 description 2
- 239000012979 RPMI medium Substances 0.000 description 2
- 102100027222 T-lymphocyte activation antigen CD80 Human genes 0.000 description 2
- 230000006786 activation induced cell death Effects 0.000 description 2
- 230000003698 anagen phase Effects 0.000 description 2
- 230000001640 apoptogenic effect Effects 0.000 description 2
- 210000003719 b-lymphocyte Anatomy 0.000 description 2
- 230000009286 beneficial effect Effects 0.000 description 2
- 229960002685 biotin Drugs 0.000 description 2
- 239000011616 biotin Substances 0.000 description 2
- 230000030833 cell death Effects 0.000 description 2
- 239000002771 cell marker Substances 0.000 description 2
- 239000006285 cell suspension Substances 0.000 description 2
- 238000011109 contamination Methods 0.000 description 2
- 238000012136 culture method Methods 0.000 description 2
- 230000001461 cytolytic effect Effects 0.000 description 2
- 230000007423 decrease Effects 0.000 description 2
- 230000000694 effects Effects 0.000 description 2
- 238000011156 evaluation Methods 0.000 description 2
- 239000012894 fetal calf serum Substances 0.000 description 2
- MHMNJMPURVTYEJ-UHFFFAOYSA-N fluorescein-5-isothiocyanate Chemical compound O1C(=O)C2=CC(N=C=S)=CC=C2C21C1=CC=C(O)C=C1OC1=CC(O)=CC=C21 MHMNJMPURVTYEJ-UHFFFAOYSA-N 0.000 description 2
- 239000008103 glucose Substances 0.000 description 2
- 238000013394 immunophenotyping Methods 0.000 description 2
- 238000000338 in vitro Methods 0.000 description 2
- 238000001727 in vivo Methods 0.000 description 2
- 230000001338 necrotic effect Effects 0.000 description 2
- 210000005259 peripheral blood Anatomy 0.000 description 2
- 239000011886 peripheral blood Substances 0.000 description 2
- 230000002688 persistence Effects 0.000 description 2
- 230000035755 proliferation Effects 0.000 description 2
- 210000003289 regulatory T cell Anatomy 0.000 description 2
- 230000002269 spontaneous effect Effects 0.000 description 2
- 238000007619 statistical method Methods 0.000 description 2
- UCSJYZPVAKXKNQ-HZYVHMACSA-N streptomycin Chemical compound CN[C@H]1[C@H](O)[C@@H](O)[C@H](CO)O[C@H]1O[C@@H]1[C@](C=O)(O)[C@H](C)O[C@H]1O[C@@H]1[C@@H](NC(N)=N)[C@H](O)[C@@H](NC(N)=N)[C@H](O)[C@H]1O UCSJYZPVAKXKNQ-HZYVHMACSA-N 0.000 description 2
- 239000000758 substrate Substances 0.000 description 2
- 230000002459 sustained effect Effects 0.000 description 2
- 238000012546 transfer Methods 0.000 description 2
- 210000004881 tumor cell Anatomy 0.000 description 2
- BZTDTCNHAFUJOG-UHFFFAOYSA-N 6-carboxyfluorescein Chemical compound C12=CC=C(O)C=C2OC2=CC(O)=CC=C2C11OC(=O)C2=CC=C(C(=O)O)C=C21 BZTDTCNHAFUJOG-UHFFFAOYSA-N 0.000 description 1
- YXHLJMWYDTXDHS-IRFLANFNSA-N 7-aminoactinomycin D Chemical compound C[C@H]1OC(=O)[C@H](C(C)C)N(C)C(=O)CN(C)C(=O)[C@@H]2CCCN2C(=O)[C@@H](C(C)C)NC(=O)[C@H]1NC(=O)C1=C(N)C(=O)C(C)=C2OC(C(C)=C(N)C=C3C(=O)N[C@@H]4C(=O)N[C@@H](C(N5CCC[C@H]5C(=O)N(C)CC(=O)N(C)[C@@H](C(C)C)C(=O)O[C@@H]4C)=O)C(C)C)=C3N=C21 YXHLJMWYDTXDHS-IRFLANFNSA-N 0.000 description 1
- 108700012813 7-aminoactinomycin D Proteins 0.000 description 1
- 102000000412 Annexin Human genes 0.000 description 1
- 108050008874 Annexin Proteins 0.000 description 1
- 108090001008 Avidin Proteins 0.000 description 1
- 208000003950 B-cell lymphoma Diseases 0.000 description 1
- 102000017420 CD3 protein, epsilon/gamma/delta subunit Human genes 0.000 description 1
- 108050005493 CD3 protein, epsilon/gamma/delta subunit Proteins 0.000 description 1
- 102100032912 CD44 antigen Human genes 0.000 description 1
- 108010001857 Cell Surface Receptors Proteins 0.000 description 1
- 241001227713 Chiron Species 0.000 description 1
- 241000132179 Eurotium medium Species 0.000 description 1
- 108010074032 HLA-A2 Antigen Proteins 0.000 description 1
- 102000025850 HLA-A2 Antigen Human genes 0.000 description 1
- 108010034115 HLA-A29 antigen Proteins 0.000 description 1
- 101000868273 Homo sapiens CD44 antigen Proteins 0.000 description 1
- 101001002657 Homo sapiens Interleukin-2 Proteins 0.000 description 1
- 101000917858 Homo sapiens Low affinity immunoglobulin gamma Fc region receptor III-A Proteins 0.000 description 1
- 101000917839 Homo sapiens Low affinity immunoglobulin gamma Fc region receptor III-B Proteins 0.000 description 1
- 101000581981 Homo sapiens Neural cell adhesion molecule 1 Proteins 0.000 description 1
- 101000716102 Homo sapiens T-cell surface glycoprotein CD4 Proteins 0.000 description 1
- 101000946843 Homo sapiens T-cell surface glycoprotein CD8 alpha chain Proteins 0.000 description 1
- 101000914514 Homo sapiens T-cell-specific surface glycoprotein CD28 Proteins 0.000 description 1
- 108010001336 Horseradish Peroxidase Proteins 0.000 description 1
- 102100029185 Low affinity immunoglobulin gamma Fc region receptor III-B Human genes 0.000 description 1
- 102100027347 Neural cell adhesion molecule 1 Human genes 0.000 description 1
- 102000004473 OX40 Ligand Human genes 0.000 description 1
- 108010042215 OX40 Ligand Proteins 0.000 description 1
- 229930182555 Penicillin Natural products 0.000 description 1
- JGSARLDLIJGVTE-MBNYWOFBSA-N Penicillin G Chemical compound N([C@H]1[C@H]2SC([C@@H](N2C1=O)C(O)=O)(C)C)C(=O)CC1=CC=CC=C1 JGSARLDLIJGVTE-MBNYWOFBSA-N 0.000 description 1
- 238000000692 Student's t-test Methods 0.000 description 1
- 102100036011 T-cell surface glycoprotein CD4 Human genes 0.000 description 1
- 102100034922 T-cell surface glycoprotein CD8 alpha chain Human genes 0.000 description 1
- 102100027213 T-cell-specific surface glycoprotein CD28 Human genes 0.000 description 1
- 229920004890 Triton X-100 Polymers 0.000 description 1
- 239000013504 Triton X-100 Substances 0.000 description 1
- 102100022153 Tumor necrosis factor receptor superfamily member 4 Human genes 0.000 description 1
- 101710165473 Tumor necrosis factor receptor superfamily member 4 Proteins 0.000 description 1
- 230000004913 activation Effects 0.000 description 1
- 239000000654 additive Substances 0.000 description 1
- 230000000996 additive effect Effects 0.000 description 1
- 230000001464 adherent effect Effects 0.000 description 1
- 108700025316 aldesleukin Proteins 0.000 description 1
- 108010004469 allophycocyanin Proteins 0.000 description 1
- 230000000890 antigenic effect Effects 0.000 description 1
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 1
- 230000003190 augmentative effect Effects 0.000 description 1
- 239000012148 binding buffer Substances 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 235000020958 biotin Nutrition 0.000 description 1
- 238000002737 cell proliferation kit Methods 0.000 description 1
- 229930002875 chlorophyll Natural products 0.000 description 1
- 235000019804 chlorophyll Nutrition 0.000 description 1
- ATNHDLDRLWWWCB-AENOIHSZSA-M chlorophyll a Chemical compound C1([C@@H](C(=O)OC)C(=O)C2=C3C)=C2N2C3=CC(C(CC)=C3C)=[N+]4C3=CC3=C(C=C)C(C)=C5N3[Mg-2]42[N+]2=C1[C@@H](CCC(=O)OC\C=C(/C)CCC[C@H](C)CCC[C@H](C)CCCC(C)C)[C@H](C)C2=C5 ATNHDLDRLWWWCB-AENOIHSZSA-M 0.000 description 1
- 230000001684 chronic effect Effects 0.000 description 1
- 230000009089 cytolysis Effects 0.000 description 1
- 210000001151 cytotoxic T lymphocyte Anatomy 0.000 description 1
- 230000001472 cytotoxic effect Effects 0.000 description 1
- 238000002784 cytotoxicity assay Methods 0.000 description 1
- 231100000263 cytotoxicity test Toxicity 0.000 description 1
- 230000003111 delayed effect Effects 0.000 description 1
- 238000000151 deposition Methods 0.000 description 1
- 230000003292 diminished effect Effects 0.000 description 1
- 238000009826 distribution Methods 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 238000003114 enzyme-linked immunosorbent spot assay Methods 0.000 description 1
- 230000000925 erythroid effect Effects 0.000 description 1
- 230000002349 favourable effect Effects 0.000 description 1
- 238000001914 filtration Methods 0.000 description 1
- 108010065889 glycyl-leucyl-cysteinyl-threonyl-leucyl-valyl-alanyl-methionyl-leucine Proteins 0.000 description 1
- 239000003102 growth factor Substances 0.000 description 1
- 230000036512 infertility Effects 0.000 description 1
- 238000001802 infusion Methods 0.000 description 1
- 208000032839 leukemia Diseases 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 239000013028 medium composition Substances 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- 102000006240 membrane receptors Human genes 0.000 description 1
- 238000000386 microscopy Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 238000010172 mouse model Methods 0.000 description 1
- 230000031942 natural killer cell mediated cytotoxicity Effects 0.000 description 1
- 239000013642 negative control Substances 0.000 description 1
- 239000001301 oxygen Substances 0.000 description 1
- 229910052760 oxygen Inorganic materials 0.000 description 1
- 229940049954 penicillin Drugs 0.000 description 1
- 230000000737 periodic effect Effects 0.000 description 1
- 229920001296 polysiloxane Polymers 0.000 description 1
- 239000002243 precursor Substances 0.000 description 1
- 102000004196 processed proteins & peptides Human genes 0.000 description 1
- 229940087463 proleukin Drugs 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- 238000003908 quality control method Methods 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 230000004044 response Effects 0.000 description 1
- 210000002966 serum Anatomy 0.000 description 1
- 229960005322 streptomycin Drugs 0.000 description 1
- 230000004083 survival effect Effects 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 238000010361 transduction Methods 0.000 description 1
- 230000026683 transduction Effects 0.000 description 1
- 241001430294 unidentified retrovirus Species 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
- C12N5/0602—Vertebrate cells
- C12N5/0634—Cells from the blood or the immune system
- C12N5/0636—T lymphocytes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K40/00—Cellular immunotherapy
- A61K40/10—Cellular immunotherapy characterised by the cell type used
- A61K40/11—T-cells, e.g. tumour infiltrating lymphocytes [TIL] or regulatory T [Treg] cells; Lymphokine-activated killer [LAK] cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K40/00—Cellular immunotherapy
- A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
- A61K40/46—Viral antigens
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2502/00—Coculture with; Conditioned medium produced by
- C12N2502/11—Coculture with; Conditioned medium produced by blood or immune system cells
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Biomedical Technology (AREA)
- General Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Genetics & Genomics (AREA)
- Immunology (AREA)
- Organic Chemistry (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Biotechnology (AREA)
- Epidemiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Veterinary Medicine (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- Microbiology (AREA)
- Cell Biology (AREA)
- Biochemistry (AREA)
- General Engineering & Computer Science (AREA)
- Hematology (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US26776109P | 2009-12-08 | 2009-12-08 | |
| US61/267,761 | 2009-12-08 | ||
| PCT/US2010/059591 WO2011072088A2 (en) | 2009-12-08 | 2010-12-08 | Improved methods of cell culture for adoptive cell therapy |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CA2783550A1 true CA2783550A1 (en) | 2011-06-16 |
Family
ID=44082417
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA2783550A Abandoned CA2783550A1 (en) | 2009-12-08 | 2010-12-08 | Improved methods of cell culture for adoptive cell therapy |
Country Status (8)
| Country | Link |
|---|---|
| US (1) | US8809050B2 (cg-RX-API-DMAC7.html) |
| EP (2) | EP2510086A4 (cg-RX-API-DMAC7.html) |
| JP (2) | JP2013512694A (cg-RX-API-DMAC7.html) |
| CN (1) | CN102762719A (cg-RX-API-DMAC7.html) |
| CA (1) | CA2783550A1 (cg-RX-API-DMAC7.html) |
| IL (1) | IL220232A0 (cg-RX-API-DMAC7.html) |
| SG (1) | SG181559A1 (cg-RX-API-DMAC7.html) |
| WO (1) | WO2011072088A2 (cg-RX-API-DMAC7.html) |
Families Citing this family (74)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ES2953434T3 (es) | 2009-08-24 | 2023-11-13 | Baylor College Medicine | Generación de líneas de CTL con especificidad frente a múltiples antígenos tumorales o múltiples virus |
| SG181559A1 (en) * | 2009-12-08 | 2012-07-30 | Wolf Wilson Mfg Corp | Improved methods of cell culture for adoptive cell therapy |
| US8956860B2 (en) | 2009-12-08 | 2015-02-17 | Juan F. Vera | Methods of cell culture for adoptive cell therapy |
| US20120244133A1 (en) | 2011-03-22 | 2012-09-27 | The United States of America, as represented by the Secretary, Department of Health and | Methods of growing tumor infiltrating lymphocytes in gas-permeable containers |
| GB201121308D0 (en) | 2011-12-12 | 2012-01-25 | Cell Medica Ltd | Process |
| US10351824B2 (en) | 2011-12-12 | 2019-07-16 | Cell Medica Limited | Process of expanding T cells |
| EP2812431B1 (en) | 2012-02-09 | 2019-07-17 | Baylor College Of Medicine | Pepmixes to generate multiviral ctls with broad specificity |
| WO2013173835A1 (en) * | 2012-05-18 | 2013-11-21 | Wilson Wolf Manufacturing Corporation | Improved methods of cell culture for adoptive cell therapy |
| SG11201407819UA (en) * | 2012-06-11 | 2014-12-30 | Wolf Wilson Mfg Corp | Improved methods of cell culture for adoptive cell therapy |
| WO2014100615A1 (en) | 2012-12-20 | 2014-06-26 | Purdue Research Foundation | Chimeric antigen receptor-expressing t cells as anti-cancer therapeutics |
| EP3004320A4 (en) | 2013-06-24 | 2017-05-17 | Wilson Wolf Manufacturing Corporation | Closed system device and methods for gas permeable cell culture process |
| AU2014324102B2 (en) | 2013-09-23 | 2021-01-28 | Wilson Wolf Manufacturing, LLC | Improved methods of genetically modifying animal cells |
| EP3154350B1 (en) | 2014-04-10 | 2024-03-27 | H. Lee Moffitt Cancer Center And Research Institute, Inc. | Enhanced expansion of tumor-infiltrating lymphocytes for adoptive cell therapy |
| HK1258649A1 (zh) | 2015-09-18 | 2019-11-15 | Baylor College Of Medicine | 来自病原体的免疫原性抗原鉴定以及与临床效力的相关性 |
| GB201522097D0 (en) | 2015-12-15 | 2016-01-27 | Cellular Therapeutics Ltd | Cells |
| CN105418766A (zh) * | 2015-12-22 | 2016-03-23 | 深圳市北科生物科技有限公司 | 一种用于免疫治疗的eb病毒lmp2a串联表位肽及其应用 |
| EP3439675A4 (en) | 2016-04-08 | 2019-12-18 | Purdue Research Foundation | METHOD AND COMPOSITIONS FOR CAR-T CELL THERAPY |
| US10052372B2 (en) * | 2016-05-24 | 2018-08-21 | Tessa Therapeutics Pte Ltd | T cell expansion |
| CA3030156A1 (en) | 2016-07-07 | 2018-01-11 | Iovance Biotherapeutics, Inc. | Programmed death 1 ligand 1 (pd-l1) binding proteins and methods of use thereof |
| KR20190066073A (ko) | 2016-10-26 | 2019-06-12 | 이오반스 바이오테라퓨틱스, 인크. | 냉동보존된 종양 침윤 림프구의 재자극 |
| TWI788307B (zh) | 2016-10-31 | 2023-01-01 | 美商艾歐凡斯生物治療公司 | 用於擴增腫瘤浸潤性淋巴細胞之工程化人造抗原呈現細胞 |
| KR102618948B1 (ko) | 2016-11-17 | 2023-12-27 | 이오반스 바이오테라퓨틱스, 인크. | 잔유 종양 침윤 림프구 및 그의 제조 및 사용 방법 |
| US11357841B2 (en) | 2017-01-06 | 2022-06-14 | Iovance Biotherapeutics, Inc. | Expansion of tumor infiltrating lymphocytes with potassium channel agonists and therapeutic uses thereof |
| WO2018129332A1 (en) | 2017-01-06 | 2018-07-12 | Iovance Biotherapeutics, Inc. | Expansion of tumor infiltrating lymphocytes (tils) with tumor necrosis factor receptor superfamily (tnfrsf) agonists and therapeutic combinations of tils and tnfrsf agonists |
| GB201700621D0 (en) | 2017-01-13 | 2017-03-01 | Guest Ryan Dominic | Method,device and kit for the aseptic isolation,enrichment and stabilsation of cells from mammalian solid tissue |
| EP3579870A4 (en) | 2017-02-07 | 2020-12-30 | Seattle Children's Hospital (DBA Seattle Children's Research Institute) | PHOSPHOLIPID ETHER (PLE) T CAR-LYMPHOCYTE TUMOR (CTCT) TARGETING AGENTS |
| CN110582288B (zh) | 2017-02-28 | 2024-09-20 | 恩多塞特公司 | 用于car t细胞疗法的组合物和方法 |
| US11254913B1 (en) | 2017-03-29 | 2022-02-22 | Iovance Biotherapeutics, Inc. | Processes for production of tumor infiltrating lymphocytes and uses of same in immunotherapy |
| JOP20190224A1 (ar) | 2017-03-29 | 2019-09-26 | Iovance Biotherapeutics Inc | عمليات من أجل إنتاج الخلايا اللمفاوية المرتشحة للأورام واستخداماتها في العلاج المناعي |
| WO2018195014A1 (en) | 2017-04-19 | 2018-10-25 | Neubiser Richard | Bioreactor for biological material |
| EP3622055A1 (en) | 2017-05-10 | 2020-03-18 | Iovance Biotherapeutics, Inc. | Expansion of tumor infiltrating lymphocytes from liquid tumors and therapeutic uses thereof |
| WO2018215936A1 (en) | 2017-05-24 | 2018-11-29 | Novartis Ag | Antibody-cytokine engrafted proteins and methods of use in the treatment of cancer |
| WO2018226714A1 (en) | 2017-06-05 | 2018-12-13 | Iovance Biotherapeutics, Inc. | Methods of using tumor infiltrating lymphocytes in double-refractory melanoma |
| CR20200251A (es) | 2017-11-17 | 2020-07-17 | Iovance Biotherapeutics Inc | Expansión de til de aspirados con aguja fina y biopsias por punción |
| CA3083118A1 (en) | 2017-11-22 | 2019-05-31 | Iovance Biotherapeutics, Inc. | Expansion of peripheral blood lymphocytes (pbls) from peripheral blood |
| WO2019118873A2 (en) | 2017-12-15 | 2019-06-20 | Iovance Biotherapeutics, Inc. | Systems and methods for determining the beneficial administration of tumor infiltrating lymphocytes, and methods of use thereof and beneficial administration of tumor infiltrating lymphocytes, and methods of use thereof |
| US11713446B2 (en) | 2018-01-08 | 2023-08-01 | Iovance Biotherapeutics, Inc. | Processes for generating TIL products enriched for tumor antigen-specific T-cells |
| US12104172B2 (en) | 2018-01-08 | 2024-10-01 | Iovance Biotherapeutics, Inc. | Processes for generating TIL products enriched for tumor antigen-specific t-cells |
| WO2019136459A1 (en) | 2018-01-08 | 2019-07-11 | Iovance Biotherapeutics, Inc. | Processes for generating til products enriched for tumor antigen-specific t-cells |
| CN112055595B (zh) | 2018-01-22 | 2024-12-17 | 恩多塞特公司 | Car t细胞的使用方法 |
| CA3090089A1 (en) | 2018-02-06 | 2019-08-15 | Seattle Children's Hospital (dba Seattle Children's Research Institute) | Fluorescein-specific cars exhibiting optimal t cell function against fl-ple labelled tumors |
| JP7568224B2 (ja) | 2018-02-23 | 2024-10-16 | エンドサイト・インコーポレイテッド | Ｃａｒ ｔ細胞療法のための配列決定法 |
| AU2018415814B2 (en) | 2018-03-29 | 2025-08-14 | Iovance Biotherapeutics, Inc. | Processes for production of tumor infiltrating lymphocytes and uses of same in immunotherapy |
| KR20210005138A (ko) | 2018-04-27 | 2021-01-13 | 이오반스 바이오테라퓨틱스, 인크. | 종양 침윤 림프구의 확장 및 유전자 편집을 위한 폐쇄 방법 및 면역요법에서의 그의 용도 |
| US12473532B2 (en) | 2018-05-10 | 2025-11-18 | Iovance Biotherapeutics, Inc. | Processes for production of tumor infiltrating lymphocytes and uses of same in immunotherapy |
| TW202031273A (zh) | 2018-08-31 | 2020-09-01 | 美商艾歐凡斯生物治療公司 | 抗ｐｄ－１抗體難治療性之非小細胞肺癌（ｎｓｃｌｃ）病患的治療 |
| KR20210064269A (ko) | 2018-09-20 | 2021-06-02 | 이오반스 바이오테라퓨틱스, 인크. | 동결보존된 종양 샘플로부터의 til의 확장 |
| KR20210099573A (ko) | 2018-11-05 | 2021-08-12 | 이오반스 바이오테라퓨틱스, 인크. | 개선된 종양 반응성 t-세포의 선택 |
| TW202039830A (zh) | 2018-11-05 | 2020-11-01 | 美商艾歐凡斯生物治療公司 | 用於製造腫瘤浸潤性淋巴細胞之方法及其在免疫療法中之用途 |
| EP3877511A1 (en) | 2018-11-05 | 2021-09-15 | Iovance Biotherapeutics, Inc. | Expansion of tils utilizing akt pathway inhibitors |
| CN112969469A (zh) | 2018-11-05 | 2021-06-15 | 艾欧凡斯生物治疗公司 | 抗pd-1抗体难治性nsclc患者的治疗 |
| US20220193131A1 (en) | 2018-12-19 | 2022-06-23 | Iovance Biotherapeutics, Inc. | Methods of Expanding Tumor Infiltrating Lymphocytes Using Engineered Cytokine Receptor Pairs and Uses Thereof |
| US20220249559A1 (en) | 2019-05-13 | 2022-08-11 | Iovance Biotherapeutics, Inc. | Methods and compositions for selecting tumor infiltrating lymphocytes and uses of the same in immunotherapy |
| US20220389381A1 (en) | 2019-10-25 | 2022-12-08 | Iovance Biotherapeutics, Inc. | Gene editing of tumor infiltrating lymphocytes and uses of same in immunotherapy |
| EP4073236A1 (en) | 2019-12-11 | 2022-10-19 | Iovance Biotherapeutics, Inc. | Processes for the production of tumor infiltrating lymphocytes (tils) and methods of using the same |
| CN115244173A (zh) | 2019-12-20 | 2022-10-25 | 英研生物(英国)有限公司 | 用于分离肿瘤浸润淋巴细胞的装置及方法及其用途 |
| BR112022021020A2 (pt) | 2020-04-22 | 2023-02-14 | Iovance Biotherapeutics Inc | Método de fabricação de um produto de terapia celular, métodos de tratamento do paciente com o produto de terapia celular de expansão e fabricado, e, método de fabricação de um produto de terapia celular |
| CA3177413A1 (en) | 2020-05-04 | 2021-11-11 | Michelle SIMPSON-ABELSON | Selection of improved tumor reactive t-cells |
| JP2023523855A (ja) | 2020-05-04 | 2023-06-07 | アイオバンス バイオセラピューティクス，インコーポレイテッド | 腫瘍浸潤リンパ球の製造方法及び免疫療法におけるその使用 |
| WO2022076606A1 (en) | 2020-10-06 | 2022-04-14 | Iovance Biotherapeutics, Inc. | Treatment of nsclc patients with tumor infiltrating lymphocyte therapies |
| CA3195019A1 (en) | 2020-10-06 | 2022-04-14 | Maria Fardis | Treatment of nsclc patients with tumor infiltrating lymphocyte therapies |
| WO2022125941A1 (en) | 2020-12-11 | 2022-06-16 | Iovance Biotherapeutics, Inc. | Treatment of cancer patients with tumor infiltrating lymphocyte therapies in combination with braf inhibitors and/or mek inhibitors |
| AU2021401302A1 (en) | 2020-12-17 | 2023-07-06 | Iovance Biotherapeutics, Inc. | Treatment with tumor infiltrating lymphocyte therapies in combination with ctla-4 and pd-1 inhibitors |
| WO2022133149A1 (en) | 2020-12-17 | 2022-06-23 | Iovance Biotherapeutics, Inc. | Treatment of cancers with tumor infiltrating lymphocytes |
| EP4326287A2 (en) | 2021-04-19 | 2024-02-28 | Iovance Biotherapeutics, Inc. | Chimeric costimulatory receptors, chemokine receptors, and the use of same in cellular immunotherapies |
| TW202327631A (zh) | 2021-07-28 | 2023-07-16 | 美商艾歐凡斯生物治療公司 | 利用腫瘤浸潤性淋巴球療法與ｋｒａｓ抑制劑組合治療癌症患者 |
| EP4423755A2 (en) | 2021-10-27 | 2024-09-04 | Iovance Biotherapeutics, Inc. | Systems and methods for coordinating manufacturing of cells for patient-specific immunotherapy |
| JP2024544867A (ja) | 2021-11-10 | 2024-12-05 | アイオバンス バイオセラピューティクス，インコーポレイテッド | Ｃｄ８腫瘍浸潤リンパ球を利用する拡張治療の方法 |
| JP2025503987A (ja) | 2022-01-28 | 2025-02-06 | アイオバンス バイオセラピューティクス，インコーポレイテッド | ペイロードを発現するように操作された腫瘍浸潤リンパ球 |
| CA3248034A1 (en) | 2022-04-15 | 2023-10-19 | Iovance Biotherapeutics, Inc. | METHODS FOR EXPANSION OF TIL CELLS BY MEANS OF SPECIFIC CYTOKINE COMBINATIONS AND/OR AKT INHIBITOR TREATMENT |
| EP4565683A1 (en) | 2022-08-01 | 2025-06-11 | Iovance Biotherapeutics, Inc. | Chimeric costimulatory receptors, chemokine receptors, and the use of same in cellular immunotherapies |
| WO2024118836A1 (en) | 2022-11-30 | 2024-06-06 | Iovance Biotherapeutics, Inc. | Processes for production of tumor infiltrating lymphocytes with shortened rep step |
| WO2024151885A1 (en) | 2023-01-13 | 2024-07-18 | Iovance Biotherapeutics, Inc. | Use of til as maintenance therapy for nsclc patients who achieved pr/cr after prior therapy |
| WO2025101484A1 (en) | 2023-11-06 | 2025-05-15 | Iovance Biotherapeutics, Inc. | Treatment of endometrial cancers with tumor infiltrating lymphocyte therapies |
Family Cites Families (23)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4649118A (en) | 1984-04-05 | 1987-03-10 | The Virtis Company, Inc. | Cell culturing apparatus with improved stirring and filter means |
| US5248769A (en) | 1985-06-26 | 1993-09-28 | Cetus Oncology Corporation | Process for recovering refractile bodies containing heterologous proteins from microbial hosts |
| US5731160A (en) * | 1992-05-26 | 1998-03-24 | Rijksuniversiteit Leiden | Induction of antigen specific T-lymphocyte responses by stimulation with peptide loaded MHC class I molecules on antigen processing defective mammalian cell lines |
| US5707869A (en) | 1994-06-28 | 1998-01-13 | Wolf; Martin L. | Compartmentalized multiple well tissue culture plate |
| US5585266A (en) | 1995-10-05 | 1996-12-17 | Plitt; Cheryl A. | Immobilized cell bioreactor |
| US5962318A (en) * | 1996-11-15 | 1999-10-05 | St. Jude Children's Research Hospital | Cytotoxic T lymphocyte-mediated immunotherapy |
| JPH10174581A (ja) | 1996-12-16 | 1998-06-30 | Kikkoman Corp | 培養容器 |
| JP3951350B2 (ja) * | 1997-04-18 | 2007-08-01 | 日立化成工業株式会社 | リンパ球細胞の製造法及び免疫治療剤 |
| JP3641123B2 (ja) * | 1997-12-26 | 2005-04-20 | 帝人株式会社 | ウィルスまたは細胞の培養法 |
| US20030235908A1 (en) | 2000-02-24 | 2003-12-25 | Xcyte Therapies, Inc. | Activation and expansion of cells |
| WO2003012085A1 (en) * | 2001-07-30 | 2003-02-13 | Sigma-Tau Industrie Farmaceutiche Riunite S.P.A. | Antigen presenting cells, method for their preparation and their use for cancer vaccines |
| US7745140B2 (en) | 2002-01-03 | 2010-06-29 | The Trustees Of The University Of Pennsylvania | Activation and expansion of T-cells using an engineered multivalent signaling platform as a research tool |
| EA010434B1 (ru) * | 2002-03-25 | 2008-08-29 | Такара Био Инк. | Способ получения цитотоксических лимфоцитов |
| US20070020752A1 (en) | 2003-05-22 | 2007-01-25 | Pall Corporation | Cell culturing device and system |
| AU2004280623B2 (en) | 2003-10-08 | 2010-12-02 | Wilson Wolf Manufacturing, LLC | Cell culture methods and devices utilizing gas permeable materials |
| US8507266B2 (en) | 2003-11-04 | 2013-08-13 | Case Western Reserve University | Apparatus and method for tissue engineering |
| JPWO2005051927A1 (ja) * | 2003-11-26 | 2007-12-06 | 株式会社クレハ | Ｈｉｖ−１感染末梢血単核球の刺激培養によるｃｄ４陽性ｔ細胞の培養方法、及びｈｉｖ−１の増殖阻害剤 |
| WO2006026746A2 (en) | 2004-08-31 | 2006-03-09 | The Government Of United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Methods to separate and expand antigen-specific t cells |
| JP4741906B2 (ja) * | 2005-08-31 | 2011-08-10 | タカラバイオ株式会社 | リンパ球の製造方法 |
| WO2008023786A1 (en) * | 2006-08-25 | 2008-02-28 | Medical & Biological Laboratories Co., Ltd. | Method for producing virus-specific ctl |
| JP5225262B2 (ja) * | 2007-02-27 | 2013-07-03 | 株式会社癌免疫研究所 | ヘルパーｔ細胞の活性化方法およびそのための組成物 |
| US9410113B2 (en) | 2007-10-26 | 2016-08-09 | St3 Development Corporation | Bioreactor system for three-dimensional tissue stimulator |
| SG181559A1 (en) * | 2009-12-08 | 2012-07-30 | Wolf Wilson Mfg Corp | Improved methods of cell culture for adoptive cell therapy |
-
2010
- 2010-12-08 SG SG2012041893A patent/SG181559A1/en unknown
- 2010-12-08 EP EP10836660.0A patent/EP2510086A4/en not_active Withdrawn
- 2010-12-08 CN CN2010800637927A patent/CN102762719A/zh active Pending
- 2010-12-08 EP EP13192463.1A patent/EP2698430A3/en not_active Withdrawn
- 2010-12-08 JP JP2012543271A patent/JP2013512694A/ja active Pending
- 2010-12-08 US US12/963,597 patent/US8809050B2/en active Active
- 2010-12-08 WO PCT/US2010/059591 patent/WO2011072088A2/en not_active Ceased
- 2010-12-08 CA CA2783550A patent/CA2783550A1/en not_active Abandoned
-
2012
- 2012-06-07 IL IL220232A patent/IL220232A0/en unknown
-
2015
- 2015-05-08 JP JP2015095864A patent/JP2015133997A/ja active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| US20110136228A1 (en) | 2011-06-09 |
| IL220232A0 (en) | 2012-07-31 |
| EP2698430A3 (en) | 2014-03-05 |
| CN102762719A (zh) | 2012-10-31 |
| US8809050B2 (en) | 2014-08-19 |
| WO2011072088A2 (en) | 2011-06-16 |
| WO2011072088A3 (en) | 2011-10-13 |
| EP2510086A4 (en) | 2013-05-22 |
| SG181559A1 (en) | 2012-07-30 |
| EP2698430A2 (en) | 2014-02-19 |
| JP2015133997A (ja) | 2015-07-27 |
| EP2510086A2 (en) | 2012-10-17 |
| JP2013512694A (ja) | 2013-04-18 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US8809050B2 (en) | Methods of cell culture for adoptive cell therapy | |
| US11999969B2 (en) | Methods of cell culture for adoptive cell therapy | |
| AU2020200037B2 (en) | Improved methods of cell culture for adoptive cell therapy | |
| AU2013274416A1 (en) | Improved methods of cell culture for adoptive cell therapy |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| EEER | Examination request |
Effective date: 20151207 |
|
| FZDE | Discontinued |
Effective date: 20171208 |